TSH BIOPHARM (stock code 8432) focused on chronic diseases and was established on September 1, 2010, to research and develop cardiovascular and autoimmune diseases with triggering and highly drug-reducible diseases. One of the most important health courses in the process of longevity and civilization is also a niche market for TSH BIOPHARM to experiment and develop. Starting from disease category management, it integrates products, research, marketing, business and training and other professional occupations, in order to become internationalized the best biopharmaceutical factory partner for R&D and marketing.
Since 2019, TSH BIOPHARM has launched a dual-engine strategy and three-track policy, and officially launched the medical field of cross-foot therapy, providing comprehensive testing services such as preventive medicine genes, diagnostic treatment testing and tracking during cancer pain treatment, and will continue to develop the disease field. The core competence extends to neurological diseases, providing all-mankind medical, post-mortem, and more excellent health services, and continues to develop high barriers, patentable and at the same time differentiation of the characteristics of drug economic effects, and continues to provide consumers and medical institutions Contributions with social significance.